PT-141 (Bremelanotide) – 10mg/vial (Research Use Only)

Overview

PT-141 (bremelanotide) is a cyclic heptapeptide agonist of the MC3R and MC4R melanocortin receptors, used in melanocortin receptor binding and signalling studies.

What It Is

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) and a metabolite of the earlier compound Melanotan II (MT-II). Molecular formula: C₅₀H₆₈N₁₄O₁₀, molecular weight approximately 1,025.19 Da, CAS number 189691-06-3. PT-141 acts as an agonist at melanocortin receptors MC3R and MC4R — receptors expressed in the central nervous system at hypothalamic and limbic sites associated with arousal and motivation circuits. Unlike Melanotan II, PT-141 does not cause significant skin tanning.

Research Spotlight

PT-141’s research trajectory began with animal pharmacology studies characterizing its melanocortin receptor binding profile and central behavioral effects in rodent models. Published preclinical research documented PT-141’s effects on behavioral parameters in rat and prairie vole models, with investigators measuring frequency and latency endpoints as surrogate measures of CNS activation. Dose-response studies characterized the MC3R/MC4R activation profile responsible for these centrally mediated observations.

Published clinical research has examined PT-141’s pharmacokinetic profile (subcutaneous absorption, plasma Tmax, elimination half-life) and safety profile across multiple cohorts. Beyond arousal pharmacology, the broader melanocortin receptor research literature — particularly MC4R biology — has examined this receptor’s roles in energy homeostasis, food intake regulation, and stress response modulation. PT-141’s selective MC3R/MC4R profile has been used as a pharmacological tool to probe these pathways in preclinical models.

Key Research Applications

• Melanocortin MC3R and MC4R receptor binding, affinity, and selectivity studies
• Central (CNS) arousal and behavioral pharmacology in rodent models
• Hypothalamic and limbic melanocortin pathway activation research
• MC4R-mediated energy homeostasis and food intake pathway investigations
• Stress response and HPA axis modulation via melanocortin receptor research
• Comparative pharmacology against MT-II and other melanocortin analogues
• Clinical pharmacokinetic reference data support (subcutaneous absorption modeling)
• Cyclic peptide stability and bioavailability research

Purity & Quality

Portal to Wellness PT-141 (Bremelanotide) is supplied to a ≥98% purity standard. Each 10mg vial provides sufficient quantity for multiple preclinical research studies. PTW does not currently publish a certificate for this compound; the current testing position is set out on our Lab Testing & Verification page. Store at −4 °F long-term.

Competitor Research Notes

PT-141’s cyclic structure introduces synthesis quality considerations not present in linear peptides. Cyclization efficiency and purity of the cyclic form (vs. linear byproduct contamination) should be verified via mass spectrometry — not just HPLC purity. Researchers should request MS confirmation of the correct cyclic structure alongside HPLC purity data. Research-grade material at ≥98% HPLC purity with MS verification is the appropriate standard for preclinical research use.

Technical Specifications

FOR RESEARCH USE ONLY. Not intended for human or veterinary consumption, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting. These statements have not been evaluated by the Food and Drug Administration.

Not sure which compounds fit your research? Browse the Research Hub →